Next Article in Journal
Implications of Intrachromosomal Amplification of Chromosome 21 on Outcome in Pediatric Acute Lymphoblastic Leukemia: Does It Affect Our Patients Too?
Previous Article in Journal
The Use of Mean Platelet Volume for Distinguishing the Causes of Thrombocytopenia in Adult Patients
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Availability of All-Trans Retinoic Acid and Support Systems for Management of Acute Promyelocytic Leukemia in Michigan and Louisiana, USA

1
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
2
Department of Hematology and Oncology, Georgia Cancer Center at Augusta University, 1411 Laney Walker Blvd, Augusta, GA, 30907, USA
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2019, 11(2), 7896; https://doi.org/10.4081/hr.2019.7896
Submission received: 1 October 2018 / Revised: 26 February 2019 / Accepted: 27 March 2019 / Published: 23 May 2019

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia with high induction mortality in the general population despite evidence of high cure rates in the clinical trials. Aggressive supportive care is essential for ideal management of these patients. We conducted a survey to collect data on these important issues required for successful treatment/outcome of APL patients from two states (Michigan and Louisiana) due to their low one-year survival rate among the Surveillance, Epidemiology, and End Results registries. All eligible hospitals (253) were obtained from the Data Medicare online directory. Availability of ATRA, formulary process to obtain it, blood back availability and established treatment protocols for the management of APL patients were queried. Since most of the hospitals surveyed do not have a treatment protocol, we believe that outcome could be improved if a standardized and simplified set of treatment and supportive care guidelines are developed for all hospitals treating APL.
Keywords: acute promyelocytic leukemia; early deaths; supportive care acute promyelocytic leukemia; early deaths; supportive care

Share and Cite

MDPI and ACS Style

Bolds, S.L.; Hassan, S.M.K.; Caprara, C.R.; Debragga, S.; Simon, K.S.; Karkhanis, P.; Gandhi, A.; Jillella, A.P.; Kota, V. Availability of All-Trans Retinoic Acid and Support Systems for Management of Acute Promyelocytic Leukemia in Michigan and Louisiana, USA. Hematol. Rep. 2019, 11, 7896. https://doi.org/10.4081/hr.2019.7896

AMA Style

Bolds SL, Hassan SMK, Caprara CR, Debragga S, Simon KS, Karkhanis P, Gandhi A, Jillella AP, Kota V. Availability of All-Trans Retinoic Acid and Support Systems for Management of Acute Promyelocytic Leukemia in Michigan and Louisiana, USA. Hematology Reports. 2019; 11(2):7896. https://doi.org/10.4081/hr.2019.7896

Chicago/Turabian Style

Bolds, Sheldon L., Shruthi M.K. Hassan, Catherine R. Caprara, Stephanie Debragga, Kathryn S. Simon, Prachi Karkhanis, Arpita Gandhi, Anand P. Jillella, and Vamsi Kota. 2019. "Availability of All-Trans Retinoic Acid and Support Systems for Management of Acute Promyelocytic Leukemia in Michigan and Louisiana, USA" Hematology Reports 11, no. 2: 7896. https://doi.org/10.4081/hr.2019.7896

Article Metrics

Back to TopTop